MORE►
immunotherapy
Video still from Lupagen's website. [Image: Lupagen}
Dallas Biotech Lupagen Partners With Global Transfusion Leader to Advance Bedside Cell and Gene Therapy
by Quincy Preston | Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
by Lance Murray |
May 17, 2023
The grant from the National Heart, Lung, and Blood Institute will fund a first-in-human Phase 1 clinical trial of a new generation of immunotherapies. This is the fourth NIH grant AyuVis has received since its founding in 2014, doubling total non-dilutive funding to $4.2 million. Co-Founder and CEO Dr. Suchismita Acharya calls the move to a human trial "a huge milestone for AyuVis."
MORE►
by Lance Murray |
Mar 9, 2023
The researchers discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs. “Now we understand that mechanism much better and, in the future, hope to use this knowledge to better fight cancer," said UT Southwestern's Andrew Y. Koh, M.D.
MORE►
by Dallas Innovates | Staff Report |
Mar 1, 2023
Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem....
MORE►
[Image: chaunpis/istockphoto]
Fort Worth’s AyuVis Is One Step Closer to Protecting Pre-Term Babies from a Leading Cause of Death
by David Kirkpatrick | Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE►
